Developing oncology biosimilars: An essential approach for the future

Seminars in Oncology

Volumn 40, Issue SUPPL.1, 2013, Pages S5-

  Abraham, Jame ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BORTEZOMIB; CETUXIMAB; DOCETAXEL; ERYTHROPOIETIN; GEMCITABINE; GENERIC DRUG; GROWTH HORMONE; LEUPRORELIN; OXALIPLATIN; PEMETREXED; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB;

ACETYLATION; ALLERGIC REACTION; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; BIOLOGICAL THERAPY; BIOTECHNOLOGY; BREAST CANCER; CANCER THERAPY; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; COLON CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; COST CONTROL; DRUG CLEARANCE; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; GOVERNMENT; HEAD AND NECK CANCER; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HYDROGEN BOND; IMMUNOGENICITY; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; METASTASIS; METHYLATION; MOLECULAR WEIGHT; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; ONCOLOGY; PATIENT CARE; PHOSPHORYLATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FOLDING; PURE RED CELL ANEMIA; RECOMBINANT DNA TECHNOLOGY; STANDARDIZATION; STOMACH ADENOCARCINOMA; UNITED STATES; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 84888391581     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.09.015     Document Type: Article

References (49)

1. A.D. Zelenetz, I. Ahmed, and E.L. Braud NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives J Natl Compr Canc Netw 9 Suppl 4 2011 S1 22
2. P.J. Declerck Biosimilar monoclonal antibodies: a science-based regulatory challenge Expert Opin Biol Ther 13 2013 153 156
3. Generics and Biosimilar Initiative. Biosimilars in oncology: current and future perspectives. gabi-journal.net/biosimilars-in-oncology-current-and- future-perspectives.html. Accessed July 24, 2013.
4. H. Schellekens Biosimilar therapeutics-what do we need to consider? NDT Plus 2 Suppl 1 2009 i27 i36
5. United States House of Representatives. United States Public Health Services Act. www.house.gov/legcoun/Comps/PHSA-CMD.pdf. Published March 13, 2013. Accessed July 19, 2013.
6. Generics and Biosimilar Initiative. FDA definitions of generics and biosimilars. http://gabionline.net/Biosimilars/General/FDA-definitions-of- generics-and-biosimilars. Accessed July 19, 2013.
7. X.Y. Cai, J. Thomas, C. Cullen, and D. Gouty Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development Bioanalysis 4 2012 2169 2177
8. J.F. Lee, J.B. Litten, and G. Grampp Comparability and biosimilarity: considerations for the healthcare provider Curr Med Res Opin 28 2012 1053 1058
9. M. Kuhlmann, and A. Covic The protein science of biosimilars Nephrol Dial Transplant 21 Suppl 5 2006 v4 v8
10. J. Kanter, and R. Feldman Understanding and incentivizing biosimilars Hastings Law J 64 2012 57 83
11. K. Verpoort, and T.M. Möhler A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre Ther Adv Med Oncol 4 2012 289 293
12. E. Ward, M. Halpern, and N. Schrag Association of insurance with cancer care utilization and outcomes CA Cancer J Clin 58 2008 9 31
13. W. Jelkmann Biosimilar epoetins and other "follow-on" biologics: update on the European experiences Am J Hematol 85 2010 771 780
14. M. McCamish, and G. Woollett The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 93 2013 315 317
15. D. Niederwieser, and S. Schmitz Biosimilar agents in oncology/ haematology: from approval to practice Eur J Haematol 86 2011 277 288
16. I. Hus Follow-on biologics in oncology-the need for global and local regulations Wspolczesna Onkol 16 2012 461 466
17. J. Wang, and S.-C. Chow On the regulatory approval pathway of biosimilar products Pharmaceuticals 5 2012 353 368
18. Generics and Biosimilar Initiative. Hurdles to biosimilars in Asia. http://gabionline.net/Biosimilars/General/Hurdles-to-biosimilars-in-Asia. Accessed July 19, 2013.
19. United States Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformatin/Guidances/UCM291134.pdf. Accessed July 19, 2013.
20. S.A. Fedewa, C. Lerro, D. Chase, and E.M. Ward Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database Gynecol Oncol 122 2011 63 68
21. S. Kozlowski, J. Woodcock, K. Midthun, and R.B. Sherman Developing the nation's biosimilars program N Engl J Med 365 2011 385 388
22. Federal Trade Commission Emerging health care issues: follow-on biologic drug competition 2009 Federal Trade Commission Washington, DC http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf Accessed July 19, 2013
23. H. Mellstedt, D. Niederwieser, and H. Ludwig The challenge of biosimilars Ann Oncol 19 2008 411 419 (Pubitemid 351325660)
24. F. Locatelli, and S. Roger Comparative testing and pharmacovigilance of biosimilars Nephrol Dial Transplant 21 Suppl 5 2006 v13 v16
25. Generics and Biosimilar Initiative. US$54 billion worth of biosimilar patents expiring before 2020. http://www.gabionline.net/Biosimilars/ Research/US-54-billion-worth-of-biosimilar-patents-expiring-before-2020. Accessed July 19, 2013.
26. F. Doloresco, C. Fominaya, and G.T. Schumock Projecting future drug expenditures: 2011 Am J Health Syst Pharm 68 2011 921 932
27. E.A. Blackstone, and J.P. Fuhr Jr Innovation and competition: will biosimilars succeed? Biotechnol Healthc 9 2012 24 27
28. M. Nowicki Basic facts about biosimilars Kidney Blood Press Res 30 2007 267 272 (Pubitemid 47482057)
29. N. Rathore, and R.S. Rajan Current perspectives on stability of protein drug products during formulation, fill and finish operations Biotechnol Prog 24 2008 504 514 (Pubitemid 351832704)
30. A.G. Vulto, and S.A. Crow Risk management of biosimilars in oncology: each medicine is a work in progress Targ Oncol 7 Suppl 1 2012 S43 S49
31. European Medicines Agency. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2013/05/WC500142978.pdf. Published May 22, 2013. Accessed July 19, 2013.
32. DrugBank. Acetylsalicylic acid. http://www.drugbank.ca/drugs/DB00945. Updated February 8, 2013. Accessed July 19, 2013.
33. DrugBank. Trastuzumab. http://www.drugbank.ca/drugs/DB00072. Updated July 14, 2011. Accessed July 19, 2013.
34. United States Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf. Accessed July 19, 2013.
35. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological- therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed July 19, 2013.
36. B.E. Strober, K. Armour, and R. Romiti Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know J Am Acad Dermatol 66 2012 317 322
37. B. Sharma Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes Biotechnol Adv 25 2007 325 331 (Pubitemid 46498674)
38. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128688.pdf. Published May 24, 2012. Accessed July 19, 2013.
39. N. Casadevall, I.R. Edwards, and T. Felix Pharmacovigilance and biosimilars: considerations, needs and challenges Expert Opin Biol Ther 13 2013 1039 1047
40. Department of Health and Human Services. Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Rockville, MD; 2005
41. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 2002 457 462 (Pubitemid 37361488)
42. N. Casadevall, J. Nataf, and B. Viron Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N Engl J Med 346 2002 469 475 (Pubitemid 34441737)
43. F. Locatelli, L. Del Vecchio, and P. Pozzoni Pure red-cell aplasia "epidemic"-mystery completely revealed? Perit Dial Int 27 Suppl 2 2007 S303 S307
44. K. Boven, S. Stryker, and J. Knight The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes Kidney Int 67 2005 2346 2353 (Pubitemid 41623396)
45. I.C. Macdougall, S.D. Roger, and A. de Francisco Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights Kidney Int 81 2012 727 732
46. V.F. Azevedo, E. Sandorff, B. Siemak, and R.J. Halbert Potential regulatory and commercial environment for biosimilars in Latin America Value in Health Regional Issues 1 2012 228 234
47. R. Mody, V. Goradia, and D. Gupta How similar are biosimilars in India? A blind comparative study Pharma Focus Asia 11 2010 www.pharmafocusasia.com/ research-development/blind-comparative-study.html Accessed July 20, 2013
48. E. Li, and J.M. Hoffman Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know J Natl Compr Canc Netw 11 2013 368 372
49. US Food and Drug Administration. Guidance for industry: formal meetings between the FDA and biosimilar biological product sponsors or applicants. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM345649.pdf. Accessed July 19, 2013.